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Background: Recent evidence suggests a subset of cells within a tumor with "stem-like" characteristics. These cells
are able to transplant tumors in immunodeficient hosts. Distinct from non-malignant stem cells, cancer stem cells
(CSC) show low proliferative rates, high self-renewing capacity, propensity to differentiate into actively proliferating
tumor cells, and resistance to chemotherapy or radiation. They are often characterized by elevated expression of
stem cell surface markers, in particular CD133, and sets of differentially expressed stem cell-associated genes. CSC
are usually rare in clinical specimens and hardly amenable to functional studies and gene expression profiling. In
this study, a panel of heterogenous melanoma cell lines was screened for typical CSC features.
Methods: Nine heterogeneous metastatic melanoma cell lines including D10 and WM115 were studied. Cell lines
were phenotyped using flow cytometry and clonogenic assays were performed by limiting dilution analysis on
magnetically sorted cells. Spheroidal growth was investigated in pretreated flasks. Gene expression profiles were
assessed by using real-time rt-PCR and DNA microarrays. Magnetically sorted tumor cells were subcutaneously
injected into the flanks of immunodeficient mice. Comparative immunohistochemistry was performed on
xenografts and primary human melanoma sections.
Results: D10 cells expressed CD133 with a significantly higher clonogenic capacity as compared to
CD133- cells. Na8, D10, and HBL cells formed spheroids on poly-HEMA-coated flasks. D10, Me39, RE, and WM115
cells expressed at least 2 of the 3 regulatory core transcription factors SOX2, NANOG, and OCT4 involved in the
maintenance of stemness in mesenchymal stem cells. Gene expression profiling on CD133+ and CD133- D10 cells
revealed 68 up- and 47 downregulated genes (+/-1.3 fold). Two genes, MGP and PROM1 (CD133), were
outstandingly upregulated. CD133+ D10 cells formed tumors in NSG mice contrary to CD133- cells and CD133
expression was detected in xenografts and primary human melanoma sections using immunohistochemistry.
Conclusions: Established melanoma cell lines exhibit, to variable extents, the typical features of CSCs. The
tumorigenic cell line D10, expressing CD133 and growing in spheroids and might qualify as a potential model of
melanoma CSCs.
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Malignant melanoma occurs in 5% of men and 4% of
women in the Western world [1]. Patients with advanced
disease have a poor prognosis with a reported median
survival ranging between 3 and 11 months [2]. In stage
IV of the disease, when patients suffer from inoperable
recurrent tumors and regional and distant metastases,
therapeutic strategies include systemic chemotherapy
and chemoimmunotherapy. Interferon-alpha and im-
mune modulators such as interleukin 2 (IL-2) and anti-
CTLA-4 (cytotoxic T-lymphocyte antigen-4) have shown
a significant clinical benefit to the patients in some pro-
spective randomized studies [3-6]. Although recent clin-
ical trials using targeted therapy (vemurafenib) suggest
promising results, the prognosis of patients with ad-
vanced disease remains poor [7]. In this context, the idea
that tumors comprise cells endowed with stem cell-like
properties, which might qualify as potential targets, is
part of ongoing research. Hamburger and his group de-
scribed, in 1977, that tumors comprise cells with hetero-
geneous tumorigenicity and differentiation potential [8].
By applying the principles of stem cell biology to cancer,
many tumors have recently been shown to be organized
hierarchically into clonally derived populations of cells
with different tumorigenic potentials. Bonnet and col-
leagues [9] were the first who could phenotypically
distinguish cells of acute myeloid leukemia (AML)
with high tumorigenicity from the remaining tumor
cells using surface markers. It was shown that only a
small subset of these cells, phenotypically similar to
hematopoietic stem cells, could transfer acute AML
when transplanted into immunodeficient mice. It was
suggested that the tumorigenic cell population repre-
sented a minority of cells within the tumor and that its
isolation could be attempted from most tumors based
on a unique surface marker expression pattern. In par-
ticular CD133 (Prominin 1), which is expressed on stem
and early progenitor cells (CD34+ hematopoietic stem
cells) and tumor-initiating cells of several malignancies
[10,11], is prominent subject of ongoing research. A few
more properties of CSCs have been identified so far, in-
cluding their common capacity to grow in anti-adhesive
structures called spheroids and a higher resistance to
hypoxia, possibly related to aberrant angiogenesis in rap-
idly expanding tumors [12,13]. Fang [14] described a
subset of cells derived from freshly isolated or in vitro
stabilized melanoma cell lines that was able to form
“melanoma spheroids” when grown in a specific stem
cell medium. Tavaluc [15] and Zhou [16] suggest that
CSCs have a higher ability to survive under hypoxic con-
ditions than normal cancer cells.
Taken together, CSCs are defined by their ability to in-
duce tumor growth following transplantation. The
tumorigenic potential of CSCs unites self-renewal anddifferentiation potential. Although some tumorigenic
phenotypes have been identified in several solid malig-
nancies so far, CSCs cannot be clearly defined by a cer-
tain morphology, genotype, or phenotype [17]. Current
cancer therapeutics based on tumor regression may tar-
get and kill differentiated tumor cells, which compose
the bulk of the tumor, while sparing the rare CSC popu-
lation. The CSC model suggests that the design of new
cancer therapeutics may require the targeting and elim-
ination of CSCs. The aim of the study was to iden-
tify CSC markers potentially allowing the functional
characterization of specific cell subsets from clinical
specimens, which have been identified in different types
of tumors, including melanoma [18]. However, the mi-
nute numbers of cells presenting these features that can
be obtained from surgical samples usually prevent a
thorough evaluation of the molecular pathways involved
in “stemness”. This background has prompted several re-
search groups to explore the possibility of taking advan-
tage of the relative heterogeneity of established cell lines
to identify cell subsets endowed with CSC features.
However, since major differences in the published xeno-
transplantation models do exist and the conclusion that
CSCs are defined by their tumorigenic potential is still
discussed controversially [19], this study focuses on the
in vitro identification and characterization of stem cell-
like cancer cells in established melanoma cell lines. We
have addressed typical phenotypical and functional CSC
features in established melanoma cell lines in order to
identify cellular reagents amenable to detailed molecular
profiling.
Results
Characterization of cell lines under investigation
The expression of melanoma associated antigens
(MAAs) was used to characterize melanoma cell lines.
The antigens of interest belonged to 2 main groups:
tumor-associated cancer testis antigens (MAGE-A3,
NY-ESO-1) and melanoma differentiation antigens (mel-
anosomal matrix protein (gp100), melanoma antigen
recognized by T cells (Melan-A/MART-1), tyrosinase)).
D10, WM115, and HBL cell line expressed the melan-
oma differentiation antigens gp100, tyrosinase, and
MART-1. These genes are also expressed in non-
transformed melanocytes. In contrast, cancer testis anti-
gens (CTA) are expressed in several malignancies of
different histological origin and are also expressed on a
few non-neoplastic cell populations including spermato-
gonia and trophoblasts, but not in healthy melanocytes.
Results are shown in Table 1. The expression analysis of
the regulatory core transcription factors NANOG,
SOX2, and OCT4 revealed that a high NANOG expres-
sion was detectable in D10, WM115, and HBL cells. Re-
sults are shown in Table 2.




gp100 tyrosinase MART-1 MAGE-A3 NY-ESO
MZ2 - - - + + -
D10 + + + + + + -
Me39 - - + + + + -
WM115 - - + + + -
RE - - - + + -
Me59 - - - +/- -
Me67 - - - + + -
Na8 - - - - -
HBL + + + + + + -
*MAA =melanoma-associated antigens; Expression levels were assessed using
conventional PCR and evaluated semiquantitatively by densitometry. gp100 =
melanosomal matrix protein gp100; tyrosinase = key enzyme in melanin
biosynthesis; MART-1 =Melan-A/MART-1 =melanoma antigen recognized by T
cells; MAGE-A3 =melanoma antigen-A3 family, NY-ESO = cancer/testis antigen
(see text); (+) =moderate expression; (+ +) = strong expression; (-) = no
expression detectable.
Table 3 Phenotypical characterization of melanoma
cell lines
Cell line CD133 CD105 CD146 CD271 CD117
MZ2 neg. 86.41 73.92 99.74 neg.
D10 89.66 77.14 98.79 neg. neg.
Me39 1.88 95.65 100.00 7.40 neg.
WM115 neg. 87.60 99.6 45.24 neg.
RE 3.11 74.84 98.31 59.96 1.28
Me59 1.00 75.55 36.40 2.72 18.95
Me67 neg. 75.94 73.76 10.75 neg.
Na8 1.05 97.22 0.67 82.54 neg.
HBL neg. 22.66 30.08 2.32 99.46
Expression levels of fluorochrome-conjugated monoclonal antibodies against
surface markers of interest on melanoma cell lines. Frequency and distribution
of cells carrying surface markers expressed as percentages of positive gated
cells; “neg.” indicates percentages of positive gated cells <1%.
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cell lines
Our data indicate that melanoma cell lines express
discrete stem cell markers. However, the distribution of
the expression was highly variable among the cell lines
under investigation (Table 3). CD133 expressing could
be detected in 5/9 melanoma cell lines including D10,
Me39, RE, Me59, and Na8, decreasing from 80-1% of
positive CD133+ subsets. Over 80% of D10 cells
expressed CD133 (Figure 1A). In addition, nearly 2% of
the Me39 cells (Figure 1B), more than 3% of RE cells
(Figure 1C), and more than 1% of Na8 (Figure 1D) and
Me59 (Figure 1E) cells also expressed CD133. Strikingly,
CD105, the TGF-β receptor, was detectable on more
than 75% of the cells of all melanoma cell lines underTable 2 Expression of regulatory core transcription
factors in melanoma cell lines
Cell line NANOG OCT4 SOX2
MZ2 - - -
D10 + + + -
Me39 + + + + -
WM115 + + +
RE + + + + -
Me59 - + -
Me67 + - -
Na8 - - -
HBL + - -
NANOG = Nanog homeobox; OCT4 = POU-domain transcription factor; SOX2=
SRY (sex determining region Y)-box2; (-) = no expression (<10-3); (+) =moderate
expression (≥10-3<10-2); (+ +)= strong expression (≥10-2). Expression level of TF
gene reported as 2–Ct, where Ct = (Ct [TF gene] - Ct [ACTB]) sample.investigation with the exception of HBL. Na8 and HBL
showed peculiar patterns of CD105, CD271, and CD117
expression. Virtually 83% of Na8 cells bound anti-
CD271 antibody as opposed to 2% of HBL cells. In stark
contrast, CD117 (c-kit) expression levels displayed an
opposite pattern with less than 1% positivity in Na8 cells
and more than 99% in HBL. In general, HBL emerged as
an outstanding cell line in our panel since virtually all
cells expressed CD117 with relatively high intensities
(Figure 1F). No other surface marker under investigation
was found to be expressed in these cells under these con-
ditions. WM115 was previously reported to contain a
CD133+ subpopulation [20]. This could not be confirmed
in our experiments. Nonetheless, 2 subpopulations were
identified in WM115. One fraction stained positive for
CD105 (88%) and another one for CD271 (45%). The cor-
responding mean fluorescence intensities (MFI values) are
attached as additional file (see Additional file 1).
D10, Na8 and HBL cells grow in spheroids
Evidence of the capacity of CSCs to grow in spheroid struc-
tures has been repeatedly reported (refer to Introduction
and Materials and Methods). To assess these features in
the melanoma cell lines under investigation, cell lines were
cultured in flasks pretreated with poly-HEMA, preventing
attachment to the plastic surface. In these conditions, the
D10 cell line - as well as the Na8 and HBL cell line - were
clearly generating spheroids (Figure 2A-C). Furthermore,
the phenotypes of these 3 cell lines were assessed upon 3D
culture. Cells were labeled again with mAbs against CD133,
CD117, CD105, CD271, and CD146; the results were com-
pared with the staining observed in cells cultured in 2D
(Table 3). Interestingly, the only modification observed in
3D as compared to the 2D cultures was represented by a
modest increase of the fraction of CD133+ cells in the Na8
cell line (Figure 3). In contrast, expression levels of CD105,
Figure 1 Expression of CD133 and CD117 in melanoma cell lines. Cell lines were stained with APC-and PE-conjugated monoclonal
antibodies against the CD133 and CD117 epitope. The figure shows the dotplots of A: D10, B: Me39, C: RE, D: Na8, E: Me59 and F: HBL.
Corresponding statistics are shown in Table 3.
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CD133 expression in D10 cells correlates with clonogenicity
Clonogenic assays were performed by limiting dilution
analysis (LDA) on cells magnetically sorted according
to their expression of selected markers (Figure 4A).
The frequency of proliferating cells was evaluated by
Poisson’s distribution. Poisson’s distribution yielded that
40.60% ± 2.63 of the CD133+ cells were capable of giving
rise to cell colonies, as opposed to 6.15% ± 0.598 of the
negative fraction (Figure 4B). CD133+ D10 cells have a
statistically significant higher clonogenic capacity as
compared to CD133- D10 cells (p ≤ 0.001). Taken to-
gether, the expression of CD105 was not associated with
a significantly higher clonogenic capacity in the cell lines
investigated. In contrast, the CD105- fraction in Me39,WM115, Na8, and HBL cell lines even dominated in
terms of clonogenic capacity, but not significantly. Ex-
cept for the RE cell line where all CD271- cells were
capable of forming colonies, CD271+ and CD271- cells
possessed equal clonogenic potential. CD117 was
expressed on almost all HBL cells. Notably, the absence
of CD117 expression was not compatible with the
in vitro survival of those cells. Referring to Poisson’s dis-
tribution, almost all HBL cells expressing CD117 are
capable of inducing colony growth.
CD133+ D10 cells induce tumor growth in vivo
D10 cells were chosen from the panel of melanoma cell
lines since they frequently expressed CD133 with a sig-
nificantly higher clonogenic capacity and for their ability
to grow in spheroids. In vivo tumor formation and
growth could be observed with CD133+ D10 cells and
Figure 2 Na8 spheroids in poly-HEMA-coated tissue culture
flasks. A: 2× magnification (scale bar 1 mm). B: 4× magnification
(scale bar 500 μm). C: 40× magnification (scale bar 50 μm).
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growth. Furthermore, isolated CD133+ D10 cells showed
an accelerated growth compared to unsorted D10 cells
(Figure 5). Xenografts induced by CD133+ D10 cells
strongly stained positive for CD133 as shown by immu-
nohistochemistry (Figure 6D). In contrast, CD133 ex-
pression in xenografts induced by unsorted D10 cells
was less intense (Figure 6C). Additionally, CD133expression was also detected in sections of a primary hu-
man melanoma (Figure 6B) and a lymph node metastasis
(Figure 6E) but hardly in normal skin sections
(Figure 6A).
MGP expression is upregulated in CD133+ D10 cells
Following chip data processing and statistical analysis
using Fisher’s ANOVA, 68 up- and 46 downregulated
genes in CD133+ as compared to CD133- D10 cells
(+/-1.3-fold, p ≤ 0.001) were obtained. The list of all differ-
entially expressed genes is provided as additional file
(Additional files 2 and 3). Two genes were outstandingly
upregulated, i.e., matrix GIa protein (MGP) and prominin
1 (PROM1, CD133). The expression of MGP in CD133+
D10 cells and the fold of change of expression in relation
to CD133- cells could be confirmed by PCR (see
Additional file 4). A number of other genes upregulated in
CD133+ D10 cells encode proteins involved in cell prolif-
eration, including insulin-like growth factor-1 (IGF-1) and
its binding protein insulin-like growth factor-binding
protein-3 (IGFBP-3). Downregulated genes included those
encoding tenascin C and TIMP1. Interestingly, the expres-
sion of BCL2A1, a gene that encodes a member of the
pro- and antiapoptotic BCL-2 protein family, was
downregulated.
Categorization of differentially expressed genes
Differentially expressed genes were categorized by their
molecular function (Figure 7A) and the biological pro-
cesses (Figure 7B) that they are involved in by using the
PANTHER classification system. Three of the 68
upregulated genes (HJURP, LL22NC03-75B3.6, and
DCC1) and 2 of the 46 downregulated genes (GOM1
and CINP) could not be identified by PANTHER. All dif-
ferentially expressed genes and their symbols are pro-
vided as additional files.
Discussion
This study aimed at investigating whether established
melanoma cell lines contain tumor cell subsets that can
be referred to as CSCs. Since CD133+ melanoma cells
are rare in clinical samples and difficult to isolate from
surgical specimens, the expression of stem cell surface
markers, in particular CD133, was analyzed in 9 well-
established human melanoma cell lines, each and every
one originally derived from human metastatic malignant
melanoma. The selection of melanoma cell lines reflects
the heterogeneity of the original tumors and includes
highly differentiated cell lines (D10, WM115, HBL) ex-
pressing the melanoma differentiation antigens gp100,
tyrosinase, and MART-1, and undifferentiated cell lines.
The melanoma cell line named WM115 was included in
the study because of its previous characterization by
Monzani’s group in 2007 [20] including a CD133+
Figure 3 CD133 expression in Na8 cells after 2D and 3D culture. Dotplots of CD133-Expression (PE-conjugated) after A: monolayer culture,
B: 3D culture (spheroidal growth). Following 3D- culture in pre-treated tissue culture flasks, almost 5% of the Na8 cells stained positive for CD133
compared to 1%.
Figure 4 Limiting dilution analysis and clonogenic assay. A: Limiting dilution analysis. Percentage of positive wells (positive well = 1 cell
colony/well) at different cell concentrations of CD133+ and CD133- D10 cells for calculating Poisson’s distribution (Figure 4B). B: Clonogenic
capacity of D10 cells. Results of Poisson’s distribution with the frequency of proliferating cells in CD133+ (black column) and CD133- (white
column) D10 cells, results expressed as mean percentages ± SD; (*) = p≤ 0.001.
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Figure 5 Tumorigenicity of D10 cells. A: The Change in tumor volume over a period of 12 weeks is shown in the graph. (*) = p≤ 0.05. Bars
represent SD. Tumor progression of CD133+ D10 cells significantly (p ≤ 0.05) differs from unsorted D10 tumors. B: Injection of CD133+ D10 cells
into the right flank (R) leads to tumor formation (white arrows) while CD133- D10 cells are not capable of inducing tumor growth. Bilateral
injection of unsorted D10 cells is followed by bilateral tumor formation.
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further characterization of our cell lines, the expression of
the regulatory core transcription factors NANOG, SOX2,
and OCT4 was analyzed. Those genes form a regulatory
core essential for maintenance of the undifferentiated stateFigure 6 Immunohistochemistry of xenografts and patient samples. C
A: normal skin section showing a few brown spots. B: primary melanoma tissue
CD133+ D10 cells, all showing intense positivity for CD133. E: xenograft inducedof stem cells and the process of stem cell self-renewal in a
complex regulatory network [22-24]. Interestingly, high
NANOG expression was detectable on the rather differen-
tiated cell lines D10, WM115, and HBL, suggesting that
either these cell lines have been misclassified previously orD133 expression (brown spots, black arrows) in different tissue samples:
section, C: melanoma lymph node metastasis and D: xenograft induced by
by unsorted D10 cells with less intense CD133+ staining. Scale bar 100 μm.
Figure 7 Categorization of differentially expressed genes, detected in CD133+ D10 cells. Number of genes encompassed with a specific
A: molecular function and B: biological process. Black columns: upregulated genes. Gray columns: downregulated genes.
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linked to the state of differentiation of individual melan-
oma cell lines. Further studies are necessary to uncover
the role of these transcription factors in melanoma cell
lines.
Melanoma cell lines do express stem cell associated
surface markers; however, their distribution was highly
variable. Surprisingly, the expression of CD133 onWM115 cells was not detectable under the conditions
used in this study. In contrast with the general thinking
that CD133+ CSCs may represent only a minimal part
of the total tumor cell population, CD133 was expressed
on high percentages of D10 cells and very small percent-
ages of Me39, RE, Me59, and Na8 cells. CD117 was
expressed on virtually all HBL cells indicating that this
might represent a specific feature of this highly
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markers used in this study revealed that only CD133+
D10 cells constantly demonstrated a significantly higher
clonogenic capacity as compared to the CD133- fraction.
The clonogenic capacity of the other markers (CD105,
CD146, and CD117) throughout the cell lines was highly
variable or oppositional in the samples examined. In a
recent publication, CD271+ melanoma stem cells were
found to be associated with metastasis, heterogeneity,
and long-term growth [25]. In our panel, CD271+ cells
could be identified in all cell lines except for D10. How-
ever, CD271+ cells did not demonstrate a significantly
higher clonogenic capacity as compared to their negative
counterparts.
Since the expression of CD133 was associated with a
significantly higher clonogenic capacity in D10 cells the
tumorigenic potential of this subset was investigated
in vivo. CD133+ and unsorted D10 cells induced tumor
formation in vivo. Shown by immunohistochemistry, xe-
nografts induced by CD133+ D10 cells stained positive
for CD133, confirming the conservation of this marker
during tumor formation. The results of our study in
which the tumorigenic potential of a CD133+ subset is
demonstrated contrary to the CD133- fraction coincides
with the classical cancer stem cell hypothesis and most
articles published in this area. However, according to re-
cent publications, the CD133- subset is also capable of
conversely inducing tumor growth upon transplantation.
Furthermore, during a suggested metastatic transition,
originally CD133- induced tumors can transform to
CD133+ xenografts. Two explanations of this phenome-
non have been suggested so far: (1) the process of tumor
initiation is a developmental process in which the
CD133- subset gains tumorigenic capacity in the host,
most likely through the influence of the adjacent envir-
onment or niche [26,27]. (2) CD133 expression does not
identify the entire population of tumor-initiating cells
[28]. In this context, future investigations on these par-
ticular CD133 subsets of D10 cells might help to both,
uncover the role of the tumor niche during tumorigen-
esis and to help to explain the phenomenon of marker
transformation in vivo.
Based on these results, gene expression profiling using
gene chips was performed on CD133+ and CD133- D10
cells. MGP (32.4-fold) and positive control PROM1
(CD133; 27.7-fold), were outstandingly upregulated
across the other 68 upregulated genes. In addition, IGF-
1 and its major corresponding binding protein IGFBP-3
were, respectively, 3.5 and 2.7-fold upregulated in
CD133+ D10 cells as compared to the CD133- fraction.
IGF-1 plays a key role in the development and growth of
multiple tumors and in the prevention of apoptosis. In
melanoma cells, IGF-1 has been shown to mediate re-
sistance to anoikis, a form of programmed cell death,which is induced by anchorage-dependent cells detach-
ing from the surrounding extracellular matrix. Recently,
Hilmi and co-workers [29] also demonstrated that IGF-1
promotes resistance to apoptosis in melanoma cells
through an increased expression of BCL2, BCL-X (L), and
survivin. Inconsistently with findings published by Fang’s
group [14], CD133+ D10 cells had not upregulated the ex-
pression of ABCG2 (ATP-binding cassette, sub-family G
(WHITE), member 2A), which was identified to be
overexpressed in primary or metastatic melanoma com-
pared to benign melanocytic nevi [18].
Conclusions
Taken together, our data suggest that established melan-
oma cell lines represent useful tools for the investigation
of functional features of CSCs. In particular, the CD133+
subset of D10 cell line with a significantly higher
clonogenic and tumorigenic capacity might qualify as
melanoma cancer stem cell model. However, since the
CD133- subset failed to induce xenografts the role of the
tumor niche for this particular subset needs to be evalu-
ated in future studies. Furthermore, gene profiling of the
CD133+ subset of the D10 melanoma cell line has
resulted in the identification of 1 gene, i.e., MGP, con-
sistently upregulated, in comparison with the CD133-
subset of the same cell line. Further in vitro and in vivo
studies are warranted to validate these results at the
gene and protein level and to assess the potential diag-
nostic and prognostic relevance of MGP, CD133, and
IGF expression in clinical melanoma specimens.
Methods
Cell culture
A panel of melanoma cell lines representative of tumors at
diverse differentiation stages was selected. All cell lines
were derived originally from metastatic melanomas. The
WM115 cell line was obtained from the ATCC; MZ2 cell
line was a gift from Dr. van der Bruggen (Brussels,
Belgium), whereas HBL, Na8, and D10 were provided by
Dr. Eberle (Basel, Switzerland). RE, Me39, Me59, and
Me67 cell lines were generated by Giulio Spagnoli’s group
(Basel, Switzerland). Cell lines were cultured in Gibco®
DMEM (Invitrogen AG, Basel, Switzerland; containing
4.5 g/L glucose and NEAA), supplemented with 10% FBS
(Invitrogen AG, Basel, Switzerland), 1% sodium pyruvate
(Invitrogen AG, Basel, Switzerland), 1% HEPES buffer
(Invitrogen AG, Basel, Switzerland), and 2% PSG
(Invitrogen AG, Basel, Switzerland). For investigating 3-
dimensional (3D) spheroidal growth, tissue culture flasks
(75 cm2, tissue culture flasks) (TPP, MIDSCI, St. Louis,
MO, USA) were pretreated with poly-HEMA (Sigma-
Aldrich®, St. Louis, MO, USA) according to the manufac-
turer’s instructions. Cell lines were also cultured in both
20% and 1% oxygen humidified atmosphere at 37°C.
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Cell suspensions from melanoma cell lines were incubated
with the following fluorochrome-conjugated antibodies:
PE/APC-CD133, FITC-CD105, APC-CD271, FITC-CD146
, and APC-CD117 (Becton-Dickinson, San José, CA, USA).
Between 5 × 105 and 5 × 106 cells per tube were labeled
with 5 μL of labeled monoclonal antibodies (mAbs) of
interest. Cells were fixed by in 1% paraformaldehyde (PAF).
The phenotype was assessed using a FACSCalibur® flow
cytometer (Becton-Dickinson).
Limiting dilution and clonogenic assay
In order to assess the possible differences in the
clonogenic capacity of cells carrying selected surface
markers, melanoma cell lines were incubated with
MicroBeads® loaded with CD105, CD133, CD271, and
CD117 (Miltenyi Biotec, Bergisch Gladbach, Germany)
and applied to columns allowing their magnetic separ-
ation into positively and negatively labeled fractions by
using a MiniMACS™ separation unit (Miltenyi Biotec,
Bergisch Gladbach, Germany) according to established
protocols. In this study, cell suspensions of melanoma
cell lines were diluted serially. Cell counts were carried
out after 14 days. In this study, positive results (positive
wells) were determined as at least 1 cell colony per well.
The frequency of proliferating cells for each target
phenotype was assessed by applying Poisson’s distribu-
tion [30]. Frequency of proliferating cells was expressed
as mean ± SD. Differences between groups were assessed
by one-way analysis of variance (ANOVA), and differ-
ences within each group were analyzed by one-way
repeated-measures ANOVA. To isolate overall differ-
ences, appropriate differences were considered signifi-
cant at p ≤ 0.001.
Animal experiments and immunohistochemistry
All animal experiments were carried out under anaesthe-
sia by intraperitoneal injections of 0.1 mL saline solution
(Sigma, Steinheim, Germany) per 10 g body weight
containing 90 mg/kg body weight ketamine hydrochlor-
ide (KetavetVR ; Parke Davis, Freiburg, Germany) and
25 mg/kg body weight dihydroxylidinothiazine hydro-
chloride (RompunVR; Bayer, Leverkusen, Germany).
Conduction of the experiments was approved by the in-
stitutional ethical committee and the Federal Office for
Consumer Protection and Food Safety with the reference
number 33.9-42502-04-11/0401. Magnetically sorted
1× 106 CD133+ D10 cells (MicroBeads®, Miltenyi Biotec,
Bergisch Gladbach, Germany) were subcutaneously
injected into the right flank regions of female NOD scid
gamma mice (NSG; NOD.Cg-Prkdcscid Il2rgtm1Wjl/
SzJ) and 1×106 CD133- D10 cells in the contralateral re-
gion. Unsorted D10 cells (1×106 cells respectively) were
bilaterally injected as control group. Eight mice wereassigned to each group. Tumor growth was assessed
once a week using a caliper and the actual tumor mass
was estimated by calculating the volume according to
the ellipsoid volume formula: 4/3 π (½ × lenght ×
width × height). Statistical analysis was carried out using
ANOVA. Mice were euthanized after 12 weeks or in case
of fulminate tumor growth. Xenografts were harvested
for immunohistochemistry. For detection of CD133
formalin-fixed specimens were embedded in paraffin and
cut into five-μm-thick sections. The sections were incu-
bated with a rabbit anti-human PROM1/CD133 antibody
(Abnova, Taipei, Taiwan). A biotin-conjugated goat anti-
rabbit antibody (Dianova, Hamburg, Germany) was used
as secondary antibody. Incubation with streptavidin–
horseradish peroxidase (Dianova) was followed by color
development with 3, 3’-diaminobenzidine (DAB) substrate
(Vector Laboratories, Burlingame, USA) at room
temperature. The sections were counterstained with
hemalaun (Merck KGaA, Darmstadt, Germany) and ex-
amined by light microscopy (DM4000B, Leica, Wetzlar,
Germany). For negative control the primary antibody was
omitted. All control stainings were negative.
Gene expression
The expression of the genes encoding the melanoma-
associated antigens (MAAs) gp100, tyrosinase, and
Melan-A/MART-1 and the cancer/testis antigens
(CTA) MAGE-A3 and NY-ESO was assessed by conven-
tional PCR, its extent was semiquantitatively evaluated by
densitometry as previously described by Spagnoli [31,32].
Primers and probes for the housekeeping gene ß-actin
(hACTB) as well as for NANOG, OCT4, SOX2, and
MAGE-3 and MGP were provided by Assays-on-Demand,
Gene Expression Products (Applied Biosystems, Foster
City, CA, USA). The other primer sequences (gp100, tyro-
sinase, Melan-A/MART-1, and NY-ESO) were derived
from existing literature, as indicated below or were gener-
ated using appropriate software (Primer Express™, Applied
Biosystems, Foster City, CA). Sequences of primers and
probes and Assays-on-Demand are attached as additional
files (see Additional files 5 and 6). TaqMan® analysis was
carried out on a 7900HT Sequence Detection System.
Singleplex PCR reactions were performed in Fast Gene
Quantification in 96-Well Plates (the thermal cycling con-
ditions included a step of 20 s at 95°C followed by 40 cycles
of 95°C for 1 s and 60°C for 20 s) with The TaqMan® Fast
Universal PCR Master Mix (10 μl) in a volume of 20 μl
containing 2 μl of cDNA and 1 μl of specific TaqMan® Gene
Expression Assay. All reactions were performed in triplicate.
All reagents were from Applied Biosystems (Foster City,
CA, USA). The comparative Ct method by Pfaffl [33] was
employed to determine the MGP expression in CD133+
and CD133- D10 cells. The MGP expression in CD133-
D10 cells was identified as a calibrator sample and the
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calibrator. Final amounts of target were determined as fol-
lows: target amount = 2–Ct, where Ct = [Ct (MGP D10
CD133+) – Ct (ACTB)]sample – [Ct (MGP D10 CD133-) –
Ct (ACTB)]calibrator.
Cell sorting for microarray studies
CD133+ and CD133- D10 cells were sorted using a
FACSVantage® Cell Sorter for genome-wide gene expres-
sion profiling. About 40 × 106 D10 cells were isolated
and resuspended in 25 μL PBS containing 2% FBS for
1 × 106 cells. Afterwards, D10 cells were labeled with
2.5 μL fluorochrome-linked mAbs against CD133
(CD133/2PE; Miltenyi Biotech, Bergisch Gladbach,
Germany) for 1 × 106 cells. D10 cells were resuspended
in 5 mL polyethylene tubes (BD Falcon™, BD Biosciences,
San Jose, CA, USA) at a concentration of 107 cells/mL in a
sorting solution. To avoid cells from sticking to the tube’s
inner surface, 5 mL polyethylene tubes were coated with
1% BSA; in order to maintain single cell suspension and
prevent cell clumping, the sorting solution based on PBS,
contained 0.5% BSA and 5 mM EDTA. CD133+ and
CD133- D10 cells were sorted out in duplicate by the
FACSVantage® cell sorter until 106 cells of each condition
were collected in the DMEM in uncoated polyethylene
5 mL tubes (BD, Falcon). The results of the cell sorting are
attached as additional file (see Additional file 7).
Microarray studies
Genome-wide gene expression profiling was carried out
according to MIAME-standards (Minimal Information
about an Array Experiment) using Affymetrix GeneChips®
Human Genome U133A 2.0 expression arrays (Affymetrix,
UK Ltd.). The experimental design and related protocols
are published in a MIAME-compliant format and can be
reviewed on ArrayExpress® (Accession Number: E-MEXP-
3542). Briefly, total RNA was isolated from previously
sorted CD133+ and CD133- D10 cells by using an RNeasy
Mini Kit (Qiagen, Basel, Switzerland) following manufac-
turer’s protocols. After elution, a total RNA cleanup was
performed using an RNeasy®MinElute® Cleanup Kit (Cat #
74204). The RNA yield was quantified by spectrophoto-
metric analysis (NanoDrop® Technologies, Wilmington,
USA) using the convention that 1 absorbance unit at
260 nm equals to 40 μg/mL RNA. Aliquots of each RNA
sample were saved for RNA fragment analysis in an
Agilent Bioanalyzer 2100® (Agilent Technologies, Basel,
Switzerland) by using an RNA 6000 Nano Kit (Agilent
Technologies, Basel, Switzerland).
Target synthesis
Biotin-labeling of RNA was performed as described in
the GeneChip® Expression Analysis Technical Manual
(Affymetrix, Santa Clara, USA). Double-stranded cDNAwas synthesized according to the One-Cycle cDNA Syn-
thesis Kit (Affymetrix, Cat # 900431), starting from 5 μg
of the total RNA. The material was purified with a Sam-
ple Cleanup Module (Affymetrix, Cat # 900371). Purified
cDNA was used for an in vitro transcription reaction by
using an IVT labeling kit (Affymetrix, Cat # 900449).
The hybridization cocktail (130 μL) containing fragmen-
ted biotin-labeled target cRNA at a final concentration
of 0.05 μg/μL was transferred into an Affymetrix Human
Genome U133A 2.0 and incubated at 45°C on a rotator
in a hybridization oven 640 (Affymetrix) for 16 h at
60 rpm. The arrays were washed and stained on a Fluid-
ics Station 450 (Affymetrix) by using a Hybridization
Wash and Stain Kit (Affymetrix, Cat # 900720). In order
to increase the signal strength, the antibody amplifica-
tion protocol (FS450_0002) was used.
Chip data processing
Gene chips were processed with an Affymetrix GeneChip®
Scanner 3000 7G (Affymetrix) and DAT image files of the
microarrays were generated using GeneChip® Operating
Software (GCOS 1.4; Affymetrix). Within GeneSpring®
raw data were preprocessed including background adjust-
ment, normalization, and summarization of probe sets,
using the GeneChip® Robust Multiarray Analysis (GC-
RMA). Genes whose signals were lower than background
in all gene chips were filtered out, subsequently genes
were filtered based on fold change. Statistical analysis on
the gene expression profile were performed by using Fish-
er’s analysis of variance (ANOVA). Profiles of genes sig-
nificantly (p ≤ 0.001) up- or downregulated (+/-1.3-fold) in
CD133+ D10 cells as compared to CD133- D10 cells were
obtained. In addition, final gene expression data were ana-
lyzed using the Protein Analysis Through Evolutionary Re-
lationships (PANTHER) classification system [34].
Additional files
Additional file 1: Phenotypical characterization of melanoma cell
lines. Corresponding mean fluorescent intensities (MFI). MFI = signal
(mAb) - signal (isotype control). No signal detected was indicated by
(neg.) when MFI < 1.
Additional file 2: Results of gene expression profiling. Table shows
significantly (p ≤ 0.001) upregulated genes (>1.3-fold) compared to
CD133- D10 cells. FC = fold change of up-regulation; RefSeq = References
to multiple sequences; ChrLoc = chromosomal location. The gene
CEACAM1 is provided as a triplet, the genes ENTPD and TPD52 as
duplicates, respectively.
Additional file 3: Results of gene expression profiling. Table shows
significantyl (p ≤ 0.001) down-regulated genes (>1.3-fold) compared to
CD133- D10 cells. FC = fold change of up-regulation; RefSeq =
References to multiple sequences; ChrLoc = chromosomal location.
Additional file 4: Real-time rt-PCR results for MGP expression in
CD133+ (black column) and CD 133- (white column) D10 cells.
(*) = p ≤ 0.05.
Additional file 5: Primers and Probes. Gp100 = melanosomal matrix
protein gp100; MART-1 = Melan-A/MART-1 = melanoma antigen
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http://www.cancerci.com/content/13/1/78recognized by T cells; tyrosinase = key enzyme in melanin biosynthesis;
NY-ESO = cancer/testis antigen (see text).
Additional file 6: Gene expression assays* for real-time RT-PCR.
*TaqMan® Gene Expression Assays (Assay-on-demand®; see Assay IDs),
Applied Biosystems ([AB], Foster City, CA); hACTB = human ACTB (beta actin)
endogenous control; NANOG = nanog homeobox; OCT4 = POU-domain
transcription factor; SOX2 = SRY (sex determining region Y)-box 2; MAGE-A3 =
melanoma antigen-A3 family; MGP = Matrix GIa protein.
Additional file 7: Results of FACSVantage® cell sorting of CD133+ and
CD133- D10 cells. Fluorochrome-linked mAbs against CD133 (CD133/2PE)
were used. A: Histogram B: dotplots.
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